E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Invasive mechanical ventilation is a lifesaving intervention among critically ill patients. However, prolonged ventilation is associated with increased morbidity and mortality. Optimal processes for weaning from ventilation have been studied for many years and have led to evidence-based clinical practice guidelines to facilitate early liberation from invasive mechanical ventilation. It is crucial to avoid prolonged MV, and weaning from the mechanical ventilator should not be delayed. |
Nei pazienti critici l'utilizzo della ventilazione meccanica è spesso necessaria e salva-vita. Nonostante ciò, la ventilazione meccanica prolungata è associata con una aumentata mortalità e morbidità. Sono stati studiati molteplici approcci finalizzati allo svezzamento precoce dalla ventilazione meccanica che hanno portato a linee guida per facilitare la sospensione precoce del supporto ventilatorio invasivo. E' essenziale evitare la ventilazione meccanica prolungata. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients admitted to Iintensive care unit and mechanically ventilated. |
Pazienti ricoverati in terapia intensiva e dipendenti dalla ventilazione meccanica. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10022519 |
E.1.2 | Term | Intensive care |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
We aim to assess if a TTS fentanyl-based sedation protocol can have an impact on the global Work of Breathing (WOB). |
Determinare se un protocollo di sedazione a base di fentanil transdermico può avere un impatto sul lavoro respiratorio. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives of the study are strudy the duration of mechanical ventilation in patients receiving TTS-fentanyl compared to remifentanil infusion as well the duration of continuous infusion of opioids, the length of stay in ICU and in hospital |
Obiettivi secondari sono studiare la durata della ventilazione meccanica nei pazienti trattati con fentanil transdermico rispetto al remifentanil in infusione continua, così come per la durata della degenza in terapia intensiva e in ospedale. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age > 18 yo • On Pressure Support Ventilation • Analgosedation with continuous infusion of remifentanil lasting 5 days or more |
• Età > 18 anni • Ventilati Meccanicamente in Pressure Support Ventilation • Remifentanil in infusione continua da 5 giorni o più |
|
E.4 | Principal exclusion criteria |
• Hypoxemic respiratory failure (P/F < 200 mmHg); • Haemodynamic instability requiring high doses of inotropes or vasopressors; • Any condition that may contraindicate the use of remifentanil or TTS-fentanyl; • Patient admitted for post-operative monitoring after elective surgery; • EAdi catheter contraindicated. |
• Insufficienza respiratoria ipossiemica (P/F < 200 mmHg) • Instabilità emodinamica che richiede farmaci inotropi o vasopressori • Ogni condizione controindicante l’uso di fentanyl TTS o remifentanil • Pazienti ammessi in reparto dopo chirurgia elettiva • Controindicazioni al posizionamento di un catetere EAdi |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint is to demonstrate that the area under the curve (AUC) of the work of breathing per minute (assessed at 1, 6, 12, 24, 48 and 72 hours) in the intervention group is not higher than the control group |
Dimostrare che l’area sotto la curva (AUC) del lavoro respiratorio per minuto (Valutato a 1, 6, 12, 24, 48 e 72 ore) nel gruppo sperimentale non è maggiore del gruppo controllo |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
72 hours from enrollment |
72 ore dall'arruolamento |
|
E.5.2 | Secondary end point(s) |
Main secondary endpoints include differences in work of breathing per breath, inspiratory effort, delta EAdi, plateau pressure, driving pressure, transpulmonary driving pressure, pulmonary complicance, P0.1, P/F ratio, respiratory rate, tidal volume, arterial blood pressure, heart rate, global duration of mechanical ventilation, length of stay in ICU and in hospital. |
Differenze di lavoro respiratorio per ogni atto, sforzo inspiratorio, delta EAdi, pressione di plateau, driving pressure, driving pressure transpolmonare, compliance polmonare, P0.1, P/F ratio, frequenza respiratoria, tidal volume, pressione arteriosa sistemica, frequenza cardiaca, durata globale della ventilazione meccanica, durata di degenza in ICU e in Ospedale. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
from enrollment to the discharge from the hospital for what concern the global duration of mechanical ventilation, length of stay in ICU and in hospital. 72 hours for the others secondary endpoints |
dall'arruolamento alla dimissione dall'ospedale per la durata di degenza in terapia intensiva/ospedale e la durata della ventilazione meccanica. 72 ore per il resto dei parametri |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 1 |